clinical trial · NCT04824092
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
Diffuse Large B-cell LymphomaTafasitamabLenalidomideRituximabCyclophosphamideDoxorubicinVincristinePrednisoneTafasitamab placebo
brief summary
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL
started
May 11, 2021
primary completion
Sep 1, 2026
completion
Nov 1, 2027
last updated
Apr 1, 2026
official title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol